| itanapraced (CHF-5074) / CereSpir |
| Completed | 2 | 96 | US, Europe | CHF 5074 1x, CHF 5074 2x, CHF 5074 3x, Placebo | CERESPIR | Alzheimer's Disease | 04/12 | 04/12 | | |
NCT01421056: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP) |
|
|
| Completed | 2 | 74 | US, Europe | CHF 5074 1x, CHF 5074 2x, CHF 5074 3x | Chiesi Farmaceutici S.p.A. | Alzheimer's Disease | 11/12 | 11/12 | | |
CT04 POLEP, NCT01602393: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase |
|
|
| Completed | 2 | 51 | US, Europe | CHF 5074 1x, CHF 5074 2x, CHF 5074 3x | Chiesi Farmaceutici S.p.A. | Alzheimer's Disease | 10/13 | 10/13 | | |
CT05, NCT01723670: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment |
|
|
| Withdrawn | 2 | 0 | US | CHF 5074 1x, CHF 5074 2x, Placebo | CERESPIR | Alzheimer's Disease | 03/16 | 03/16 | | |
